Multi-billion FTSE newcomer Haleon shows there is life after GSK Two months since FTSE float The owner of popular health products such as Sensodyne and Panadol said this a.m. its revenues have jumped up by more than 13 per cent, to a record £5.2bn, during the first half of the year. Healthcare giant Haleon further reported a double-digit hike in profits in the group’s first-ever set of company results since [...]
Changes sweep the boardrooms and C-suites of biggest businesses in the UK overhaul The boardrooms and C-suites of some of largest companies in the UK have undergone sweeping overhauls this week alone. The winds of change have blown as the country heads into autumn and buckles down for a worsening economic crisis, some two years on from the start of the pandemic. While Covid-19 measures in the country [...]
GSK shares float above recent lows amid looming legal woes glaxosmithkline British pharmaceutical giant GlaxoSmithKline (GSK) has been wrapped up with legal woes this week over recalled heartburn drug Zantac and a former AstraZeneca dealmaker – which have wiped billions off its market value. London-listed GSK’s shares have dipped into the red slightly today but remained above recent lows. However, the company has lost nearly eight [...]
UK government must wake up to clinical research slowdown, industry body warns July 31, 2022 A slowdown in clinical research could hold Britain back in its bid to become a life sciences superpower, an industry body has warned. In a letter to Rishi Sunak and Liz Truss, the Association of the British Pharmaceutical Industry (ABPI) said “alarm bells” should be ringing across the government, the Sunday Telegraph reported. The letter [...]
Ex-GSK Haleon lands on London market despite economic turbulence July 18, 2022 Haleon, GlaxoSmithKline’s (GSK) former consumer health division, will list on the London market today as a standalone entity. It is a sign of changing tides on the London Stock Exchange, which for years has heavily relied on oil, mining and financial firms. The new FTSE healthcare heavyweight, which awaits a response on its application to [...]
Landmark year: GSK beats quarterly expectations as it plans consumer healthcare spin off April 27, 2022 Healthcare giant GlaxoSmithKline has reiterated its growth outlook after posting first quarter sales of £9.8bn, surpassing analysts’ expectations. The pharmaceutical firm said it anticipated it would deliver sales growth in 2022 of between five to seven per cent at CER and growth of adjusted operating profit of between 12 to 14 per cent at CER. [...]
GlaxoSmithKline clinches cancer specialist Sierra Oncology in $1.9bn deal April 13, 2022 Healthcare giant GSK has snapped up Sierra Oncology, a late-stage biopharmaceutical company focused on rare forms of cancer treatments.
GlaxoSmithKline will not begin any new clinical trials in Russia March 18, 2022 Britain’s second-biggest drug maker, GlaxoSmithKline, won’t begin any new clinical trials in Russia because of the war against Ukraine. It made the announcement following similar moves by major US pharmaceutical giants Pfizer, Merck and Eli Lilly. The UK’s biggest company in the industry, AstraZeneca, is still conducting trials – but is considering ending them, according [...]
GSK looks for covid jab approval as it prepares to spin off consumer arm February 23, 2022 GlaxoSmithKline and French drugmaker Sanofi have announced they are seeking regulatory approvals for their joint covid vaccine as the firms scramble to catch up with competitors after a series of delays.
GlaxoSmithKline revels in £8.8bn profit ahead of consumer healthcare demerger February 9, 2022 GlaxoSmithKline (GSK) has reported full-year sales of £34bn, boosted by strong pharmaceutical sales over the past 12 months.